LT2736887T - Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas - Google Patents

Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas

Info

Publication number
LT2736887T
LT2736887T LTEP12743846.3T LT12743846T LT2736887T LT 2736887 T LT2736887 T LT 2736887T LT 12743846 T LT12743846 T LT 12743846T LT 2736887 T LT2736887 T LT 2736887T
Authority
LT
Lithuania
Prior art keywords
nuclear transport
containing nuclear
hydrazide containing
transport modulators
modulators
Prior art date
Application number
LTEP12743846.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Vincent P. SANDANAYAKA
Sharon Shacham
Dilara Mccauley
Sharon Shechter
Original Assignee
Karyopharm Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics, Inc. filed Critical Karyopharm Therapeutics, Inc.
Publication of LT2736887T publication Critical patent/LT2736887T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
LTEP12743846.3T 2011-07-29 2012-07-26 Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas LT2736887T (lt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513432P 2011-07-29 2011-07-29
US201161513428P 2011-07-29 2011-07-29
US201261610178P 2012-03-13 2012-03-13
US201261653588P 2012-05-31 2012-05-31
US201261654651P 2012-06-01 2012-06-01
PCT/US2012/048319 WO2013019548A1 (en) 2011-07-29 2012-07-26 Hydrazide containing nuclear transport modulators and uses thereof

Publications (1)

Publication Number Publication Date
LT2736887T true LT2736887T (lt) 2018-02-12

Family

ID=46634546

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12743846.3T LT2736887T (lt) 2011-07-29 2012-07-26 Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas
LTPA2021007C LTC2736887I2 (enExample) 2011-07-29 2021-07-30

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2021007C LTC2736887I2 (enExample) 2011-07-29 2021-07-30

Country Status (35)

Country Link
US (9) US9079865B2 (enExample)
EP (3) EP2736887B1 (enExample)
JP (3) JP6005740B2 (enExample)
KR (7) KR20240060688A (enExample)
CN (5) CN103874690B (enExample)
AR (1) AR087342A1 (enExample)
AU (6) AU2012290454B2 (enExample)
BR (1) BR112014001934B1 (enExample)
CA (1) CA2842362C (enExample)
CL (2) CL2014000225A1 (enExample)
CO (1) CO6960539A2 (enExample)
CY (2) CY1119783T1 (enExample)
DK (2) DK3333164T3 (enExample)
EA (1) EA201490407A1 (enExample)
ES (2) ES2655645T3 (enExample)
FR (1) FR21C1042I2 (enExample)
GE (1) GEP201706616B (enExample)
HR (1) HRP20180014T1 (enExample)
HU (2) HUE036058T2 (enExample)
LT (2) LT2736887T (enExample)
LU (1) LUC00219I2 (enExample)
ME (1) ME02936B (enExample)
MX (2) MX378433B (enExample)
NL (1) NL301119I2 (enExample)
NO (1) NO2021033I1 (enExample)
PE (1) PE20141170A1 (enExample)
PL (2) PL3333164T3 (enExample)
PT (1) PT2736887T (enExample)
RS (1) RS56823B1 (enExample)
SI (1) SI2736887T1 (enExample)
SM (1) SMT201800171T1 (enExample)
TW (1) TWI574957B (enExample)
UA (1) UA115532C2 (enExample)
WO (1) WO2013019548A1 (enExample)
ZA (1) ZA201401223B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
ES2655645T3 (es) 2011-07-29 2018-02-21 Karyopharm Therapeutics, Inc. Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos
CA2842364A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
KR101629233B1 (ko) 2012-01-18 2016-06-10 (주)바이오니아 자성나노입자-SAMiRNA 복합체 및 그 제조방법
PL3404027T3 (pl) * 2012-05-09 2020-09-21 Biogen Ma Inc. Modulatory transportu jądrowego i ich zastosowania
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
LT3010892T (lt) * 2013-06-21 2019-04-10 Karyopharm Therapeutics Inc. 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015002512A1 (ko) 2013-07-05 2015-01-08 (주)바이오니아 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물
WO2015002511A1 (ko) 2013-07-05 2015-01-08 (주)바이오니아 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2739637T3 (es) * 2013-11-28 2020-02-03 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de beta-talasemias
ES2984979T3 (es) 2014-04-04 2024-10-31 Bioneer Corp Oligo ARN de doble cadena y composición farmacéutica que comprende el mismo para la prevención o tratamiento de fibrosis o enfermedades respiratorias
DK3180331T3 (da) * 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US11065230B2 (en) 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831617A (zh) * 2017-01-17 2017-06-13 广州市闻皓生物科技有限公司 一种Selinexor中间体的合成工艺
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2018191707A2 (en) * 2017-04-13 2018-10-18 Brown University Nucleocytoplasmic regulator of autophagy-associated transcription factors
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN108947982A (zh) * 2018-08-16 2018-12-07 刘璐 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CA3130107A1 (en) 2019-03-20 2020-09-24 Johnson Matthey Public Limited Company Co-crystal forms of selinexor
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
SG11202111993SA (en) * 2019-05-01 2021-11-29 Karyopharm Therapeutics Inc Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2021163338A1 (en) 2020-02-11 2021-08-19 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
US11180473B2 (en) 2020-03-27 2021-11-23 Landos Biopharma, Inc. PLXDC2 ligands
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252905A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in diffuse large b-cell lymphoma patients
WO2021252900A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2021252874A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
WO2022232417A1 (en) 2021-04-28 2022-11-03 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2022246065A1 (en) 2021-05-19 2022-11-24 Karyopharm Therapeutics Inc. Calb1 biomarker in the treatment of de-differentiated liposarcoma using xpo1 inhibitors, such as selinexor
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection
CN116625976B (zh) * 2023-04-10 2025-11-21 南京农业大学 一种微生物浓度的监测系统及方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
JPS5661360A (en) * 1979-10-25 1981-05-26 Teijin Ltd 1-substituted imidazole derivative and its preparation
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
AU2178497A (en) 1996-04-04 1997-10-29 Shionogi & Co., Ltd. Cephem compounds and drugs containing the compounds
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
KR20050062645A (ko) * 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 신경병증의 예방 또는 치료제
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
AU2005272389B2 (en) 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
ZA200803758B (en) 2005-11-15 2009-08-26 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
US8404726B2 (en) 2006-04-18 2013-03-26 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor δ
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US8653115B2 (en) 2006-06-13 2014-02-18 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
PT2090570E (pt) 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Derivado de imidazole
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP2124927A2 (en) 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2655645T3 (es) 2011-07-29 2018-02-21 Karyopharm Therapeutics, Inc. Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
PL3404027T3 (pl) 2012-05-09 2020-09-21 Biogen Ma Inc. Modulatory transportu jądrowego i ich zastosowania
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
LT3010892T (lt) 2013-06-21 2019-04-10 Karyopharm Therapeutics Inc. 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
CN105294681B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
DK3180331T3 (da) 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
US20200339521A1 (en) 2020-10-29
AU2022203265A1 (en) 2022-06-02
US10544108B2 (en) 2020-01-28
LTC2736887I2 (enExample) 2022-10-25
LUC00219I2 (enExample) 2022-10-07
US8999996B2 (en) 2015-04-07
JP6675431B2 (ja) 2020-04-01
PE20141170A1 (es) 2014-09-16
JP6309057B2 (ja) 2018-04-11
ME02936B (me) 2018-04-20
JP6005740B2 (ja) 2016-10-12
BR112014001934B1 (pt) 2020-12-15
JP2018111713A (ja) 2018-07-19
CY2021028I1 (el) 2022-03-24
US9206158B2 (en) 2015-12-08
CY2021028I2 (el) 2022-03-24
FR21C1042I2 (fr) 2022-09-02
CN117229268A (zh) 2023-12-15
US20140235653A1 (en) 2014-08-21
CA2842362A1 (en) 2013-02-07
EP3333164B1 (en) 2023-06-07
KR20210083380A (ko) 2021-07-06
CN103874690B (zh) 2016-07-06
NL301119I1 (enExample) 2021-08-04
MX378433B (es) 2025-03-11
US12291508B2 (en) 2025-05-06
US20140364408A1 (en) 2014-12-11
WO2013019548A1 (en) 2013-02-07
AU2024202868A1 (en) 2024-05-23
CN110372673A (zh) 2019-10-25
FR21C1042I1 (enExample) 2021-11-19
NO2021033I1 (no) 2021-09-06
AU2016210682B2 (en) 2018-04-19
MX349712B (es) 2017-08-09
CN110372672A (zh) 2019-10-25
AU2012290454B2 (en) 2016-05-05
MX2014001181A (es) 2014-07-14
SI2736887T1 (en) 2018-04-30
KR20190045399A (ko) 2019-05-02
TW201311666A (zh) 2013-03-16
AU2018202441A1 (en) 2018-04-26
SMT201800171T1 (it) 2018-07-17
ZA201401223B (en) 2022-03-30
RS56823B1 (sr) 2018-04-30
KR20250008805A (ko) 2025-01-15
BR112014001934A2 (pt) 2017-02-21
NL301119I2 (nl) 2021-09-15
US20190330164A1 (en) 2019-10-31
TWI574957B (zh) 2017-03-21
AU2012290454A1 (en) 2014-03-20
GEP201706616B (en) 2017-02-10
KR20230042129A (ko) 2023-03-27
NZ621904A (en) 2016-05-27
HK1256745A1 (en) 2019-10-04
CN110372672B (zh) 2023-09-29
EP2736887A1 (en) 2014-06-04
CN110372673B (zh) 2023-10-03
US9714226B2 (en) 2017-07-25
CN106083827A (zh) 2016-11-09
KR20240060688A (ko) 2024-05-08
HUS2100030I1 (hu) 2021-09-28
AU2020203121A1 (en) 2020-05-28
US11787771B2 (en) 2023-10-17
US20150274698A1 (en) 2015-10-01
PL3333164T3 (pl) 2023-12-18
KR102022716B1 (ko) 2019-09-18
EA201490407A1 (ru) 2014-05-30
CY1119783T1 (el) 2018-06-27
CN106083827B (zh) 2019-09-17
EP4234545A3 (en) 2023-09-06
CN103874690A (zh) 2014-06-18
CL2015001257A1 (es) 2015-09-21
LTPA2021007I1 (enExample) 2021-08-25
JP2014521652A (ja) 2014-08-28
US20220073478A1 (en) 2022-03-10
EP4234545A2 (en) 2023-08-30
US9079865B2 (en) 2015-07-14
CA2842362C (en) 2020-06-16
HUE036058T2 (hu) 2018-06-28
ES2655645T3 (es) 2018-02-21
US10173987B2 (en) 2019-01-08
US20180127384A1 (en) 2018-05-10
AR087342A1 (es) 2014-03-19
EP2736887B1 (en) 2017-10-18
DK3333164T3 (da) 2023-09-18
ES2954991T3 (es) 2023-11-28
AU2018202441B2 (en) 2020-02-13
US20160304472A1 (en) 2016-10-20
UA115532C2 (uk) 2017-11-27
KR20200088518A (ko) 2020-07-22
KR102136768B1 (ko) 2020-07-23
CO6960539A2 (es) 2014-05-30
EP3333164A1 (en) 2018-06-13
AU2016210682A1 (en) 2016-08-18
US20240279188A1 (en) 2024-08-22
JP2017036287A (ja) 2017-02-16
KR20140066179A (ko) 2014-05-30
PL2736887T3 (pl) 2018-03-30
PT2736887T (pt) 2018-01-15
NZ719623A (en) 2017-12-22
HRP20180014T1 (hr) 2018-04-20
CL2014000225A1 (es) 2014-12-05
AU2020203121B2 (en) 2022-02-17
HK1198477A1 (en) 2015-05-08
DK2736887T3 (en) 2018-01-02
US11034660B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
ZA201401223B (en) Hydrazide containing nuclear transport modulators and uses thereof
ZA202004892B (en) Nuclear transport modulators and uses thereof
SG10201609097PA (en) Nuclear transport modulators and uses thereof
EP2665362A4 (en) NUCLEAR TRANSPORTER MODULATORS CONTAINING OLEFINS AND USES THEREOF
IL261612A (en) Nuclear transfer modulators and their uses
ZA201308930B (en) Nitrogen containing compounds and their use
ZA201308759B (en) Developer replenishment container and developer replenishment system
ZA201307261B (en) Active materials for electro-optic devices and electro-optic devices
ZA201306675B (en) Transport and presentation crate
EP2720664A4 (en) BOTTLE STORAGE AND MIXING
EP2668084A4 (en) HANDLING AND TRANSPORT SYSTEM
SG10201602149XA (en) SALL4 And Uses Thereof
ZA201400406B (en) Trans-clomiphene metabolites and uses thereof
ZA201402761B (en) Packing system and use thereof
IL228268B (en) Methods and devices for treating biofouling
PL393600A1 (pl) Kontener transportowo-magazynowy
GB2485537B8 (en) Integral - surface and air - personal transport
GB201122034D0 (en) Apparatus for the storage and transport of bags
GB201213345D0 (en) Means for storage and transportation